Clearside Biomedical Inc’s filing revealed that its Director Thorp Clay acquired Company’s shares for reported $13800.0 on Feb 24 ’25. In the deal valued at $0.92 per share,15,000 shares were bought. As a result of this transaction, Thorp Clay now holds 176,141 shares worth roughly $0.14 million.
Then, Chong Ngai Hang Victor bought 36,500 shares, generating $36,500 in total proceeds. Upon buying the shares at $1.00, the Chief Medical Officer now owns 100,000 shares.
Before that, Chong Ngai Hang Victor bought 23,500 shares. Clearside Biomedical Inc shares valued at $24,910 were divested by the Chief Medical Officer at a price of $1.06 per share. As a result of the transaction, Chong Ngai Hang Victor now holds 63,500 shares, worth roughly $49530.0.
Chardan Capital Markets initiated its Clearside Biomedical Inc [CLSD] rating to a Buy in a research note published on August 21, 2024; the price target was $6. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. H.C. Wainwright started covering the stock on July 29, 2021. It rated CLSD as “a Buy”.
Price Performance Review of CLSD
On Friday, Clearside Biomedical Inc [NASDAQ:CLSD] saw its stock jump 1.85% to $0.78. Over the last five days, the stock has gained 5.46%. Clearside Biomedical Inc shares have fallen nearly -18.41% since the year began. Nevertheless, the stocks have fallen -34.87% over the past one year.
Levels Of Support And Resistance For CLSD Stock
The most recent change occurred on May 13, 2020 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
